Hagens Berman has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential securities law violations after the company’s shares dropped 59% on August 7, 2026.

The legal review follows a series of operational setbacks disclosed after market close on August 6, including a U.S. Department of Justice Civil Investigative Demand (CID), significant revenue guidance cuts, and the abrupt termination of Chief Revenue Officer Robert John on August 10, 2026.

Investigation Focus

The firm is examining whether CVRx misled investors about the health of its commercial sales force and Medicare Advantage reimbursement rates. Partner Reed Kathrein stated the investigation will assess the connection between the DOJ CID and the CRO’s dismissal.

Key issues under scrutiny include:

• A CID received on May 14, 2026, investigating potential false claims related to the marketing of Barostim, an implantable neuromodulation device for heart failure.
• Allegations of kickbacks to healthcare providers and submission of false information to government health programs.
• Discrepancies between earlier assurances of a "largely complete" sales force transformation and subsequent disclosures of sequential flat growth in sales territories and high turnover.

Operational Headwinds

CVRx reported severe disruptions in its primary revenue drivers. The company’s main Medicare Advantage payer reduced initial approval rates from 80% to just 25% within 30 days, citing increased denials.

What the Numbers Show

The divergence between CVRx’s earlier market positioning and its recent disclosures highlights a sharp reversal in commercial execution. The firm previously anchored its growth strategy on a $10.5 billion market opportunity with less than 1% penetration and a transformed sales force. The simultaneous collapse of Medicare approvals to 25% and the admission of sales force strain suggest the earlier "complete" transformation claims may not have reflected underlying operational realities at the time of disclosure.

Investor Action

Investors who suffered losses are encouraged to submit their details to evaluate legal rights. Whistleblowers with non-public information may also contact the firm regarding potential SEC whistleblower program rewards.

Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in CVRx, Inc. (NASDAQ: CVRX). The probe follows significant stock declines and revised revenue guidance.

The investigation centers on whether the company and its officers engaged in unlawful business practices. It stems from a series of negative developments between April 2025 and August 2026.

Timeline of Declines

On April 7, 2025, CVRx announced weaker than expected preliminary first quarter results. CEO Hykes noted that many newer sales representatives were still in early development stages. The stock fell $5.34 per share, or 46.3%, to close at $6.20 per share on April 8, 2025.

In May 2025, the company reported weak first quarter results and lowered full year revenue guidance. Hykes stated that salesforce changes were more significant than anticipated, with 25% of current territory managers hired between December and March. The stock dropped $3.01 per share, or 38.7%, to close at $4.77 per share on May 9, 2025.

August 2026 Guidance Cut

On August 6, 2026, CVRx lowered its full-year revenue guidance to $58 million-$60 million from $63 million-$67 million. Management attributed this to rapid hiring straining onboarding processes and territory manager productivity ramp rates.

Management stated that slightly less than half of CVRx's regions experienced negative year-to-date implant growth. These regions had the highest turnover and least-tenured leaders. The company also cited a prolonged challenge with one of its largest Medicare Advantage payers.

Additionally, CVRx disclosed receiving a Department of Justice civil investigative demand in May 2026 concerning certain sales and marketing practices. Following this news, the stock fell $3.55 per share, or 59.76%, to close at $2.39 per share on August 7, 2026.

What the Numbers Show

The correlation between operational disclosures and stock performance is stark. Each major update regarding salesforce instability or regulatory scrutiny triggered double-digit percentage declines. The August 2026 drop of nearly 60% was the largest single-day decline recorded in the source, coinciding with both a material guidance reduction and the DOJ investigation disclosure.

Legal Context

Pomerantz LLP, founded by Abraham L. Pomerantz, specializes in corporate and securities class litigation. The firm has offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.